Medications for Substance Use Disorders

被引：38

作者：

Douaihy, Antoine B. ^{[1
]}

Kelly, Thomas M. ^{[2
]}

Sullivan, Carl ^{[3
]}

机构：

[1] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Sch Med, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Ctr Psychiat & Chem Dependency Serv, Med Ctr, Pittsburgh, PA 15213 USA

[3] W Virginia Univ, Addict Program, Morgantown, WV 26506 USA

来源：

SOCIAL WORK IN PUBLIC HEALTH | 2013年 / 28卷 / 3-4期

关键词：

Substance use disorders; detoxification; relapse prevention; nicotine; alcohol; opioids; social workers; SUSTAINED-RELEASE BUPROPION; PLACEBO-CONTROLLED TRIAL; RECEPTOR PARTIAL AGONIST; ALCOHOL-DEPENDENCE; SMOKING-CESSATION; DOUBLE-BLIND; NALTREXONE; EFFICACY; PHARMACOTHERAPY; DISULFIRAM;

D O I：

10.1080/19371918.2013.759031

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

In this article, the authors briefly review the pharmacotherapeutic agents that are currently available for the treatment of substance use disorders. Nicotine replacement therapies are most effective for tobacco cessation. Naltrexone, acamprosate, and disulfiram are effective for reducing alcohol use. The most effective pharmacotherapies for opiate use disorders are agonist therapies, including methadone and buprenorphine. The authors also examine recent advances in medication development for other substance use disorders such as stimulant addiction. The role of medication adherence and behavioral treatments and the integration of behavioral and pharmacotherapeutic interventions are also discussed.

引用

页码：264 / 278

页数：15

共 50 条

[21] Substance Use disorders
Terry, M
DRUG AND ALCOHOL REVIEW, 2002, 21 (02) : 187 - 187
[22] Epidemiology of substance use and substance use disorders in Germany
Kuefner, H.
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2010, 53 (04) : 271 - 283
[23] Long-Acting Injectable Antipsychotic Medications in Patients With Comorbid Schizophrenia and Substance Use Disorders
Green, Alan I.
JOURNAL OF DUAL DIAGNOSIS, 2012, 8 (01) : 62 - 63
[24] Substance Use Disorders Are Psychiatric Disorders
Balasanova, Alena A.
AMERICAN JOURNAL OF PSYCHIATRY, 2023, 180 (12): : 918 - 918
[25] A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co-morbid substance use disorders
Kollins, Scott H.
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1345 - 1357
[26] Medications for Alcohol Use Disorders Reply
Bradley, Katharine
Kivlahan, Daniel
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (13): : 1352 - 1352
[27] Medications development for alcohol use disorders
Wright, C
PSYCHOPHARMACOLOGY BULLETIN, 1995, 31 (04) : 681 - 686
[28] Diachronic substance use assessment and the emergence of substance use disorders
Clark, DB
Pollock, NK
Mezzich, A
Cornelius, J
Martin, C
JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE, 2001, 10 (04) : 13 - 22
[29] Estimating the economic consequences of substance use and substance use disorders
Manthey, Jakob
Hassan, Syed Ahmed
Carr, Sinclair
Kilian, Carolin
Kuitunen-Paul, Soeren
Rehm, Juergen
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 869 - 876
[30] Medications for alcohol use disorders: An overview
Akbar, Mohammed
Egli, Mark
Cho, Young-Eun
Song, Byoung-Joon
Noronha, Antonio
PHARMACOLOGY & THERAPEUTICS, 2018, 185 : 64 - 85

← 1 2 3 4 5 →